ClinicalTrials.gg
CompletedNCT04432831Rhone-XUpdated Feb 9, 2026Results posted

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

A Phase 3 interventional study of Faricimab and Sham Procedure in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 320 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,479
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.

Enrollment
Largest of 13
1,479 · median 229
Started
2020
with 1 other
Phase 3
7 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
8 of 13
Hoffmann-La Roche

Among the 13 studies testing faricimab in Macular Edema, this one has the largest enrollment, is one of 2 that started in 2020, is one of 7 in phase 3, and was the 5th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:

About faricimab

faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing faricimab in Macular Edema, or all of them as a file.
02

Study summary

This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI) to participants who enrolled in and completed one of the two Phase III studies, GR40349 (NCT03622580) or GR40398 (NCT03622593), also referred to as the parent studies.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous enrollment in and completion of Study GR40349 (NCT03622580) or GR40398 (NCT03622593), without study or study drug discontinuation
  • Ability to comply with the study protocol, in the investigator's judgment
  • For women of : agreement to remain abstinent or use acceptable methods that result in a failure rate of \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final intravitreal injection of faricimab
  • Presence of other ocular diseases that give reasonable suspicion of a disease or condition that contraindicates the use of faricimab, that might affect interpretation of the results of the study or that renders the patient at high risk for treatment complications
  • Presence of other diseases, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of faricimab and that might affect interpretation of the results of the study or that renders the patient at high risk of treatment complications
  • History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the faricimab injections, study treatment procedure, dilating drops, or any of the anesthetic and antimicrobial preparations used by a patient during the study
  • Requirement for continuous use of any medications or treatments indicated as prohibited therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,479 participants (actual)

Study arms

  • Experimental
    Faricimab PTI

    Drug: Faricimab · Other: Sham Procedure

Interventions

  • Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.

    Also known as: RO6867461, RG7716

  • OtherSham Procedure

    The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale

    This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)

  2. Incidence of Ocular Adverse Events in the Fellow Eye

    This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the fellow eye (i.e., non-study eye). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity, and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)

  3. Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading Scale

    This is an analysis of participants with at least one non-ocular (systemic) adverse event (AE). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)

07

Results

Posted Oct 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneFaricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)
Started493506475
Received at least one dose of study drug491500473
Completed405407392
Not completed889983
Withdrew: Withdrawal by subject242821
Withdrew: Death232317
Withdrew: Lost to follow-up151512
Withdrew: Final end of study visit not completed10117
Withdrew: Reason not specified7119
Withdrew: Adverse event777
Withdrew: Physician decision136
Withdrew: Protocol violation102
Withdrew: Pregnancy010
Withdrew: Lack of efficacy002

Outcome measures

PrimaryIncidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale

This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
Reported as:
Count of participants · Participants
Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale
ParticipantsFaricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)
Any Adverse Event (AE), Any Severity219188197
AE by Severity: Mild119109109
AE by Severity: Moderate746674
AE by Severity: Severe201012
AE by Severity: Missing632
Serious Adverse Event (SAE)311526
AE Leading to Withdrawal from Study Treatment306
Treatment-related AE101011
Treatment-related SAE011
Any AE of Special Interest (AESI)301424
AESI: Drop in Visual Acuity Score ≥30 Letters231020
AESI: Associated with Severe IOI111
AESI: Intervention Required to Prevent Permanent Vision Loss633
AESI: Suspected Transmission of Infectious Agent by Study Drug000
PrimaryIncidence of Ocular Adverse Events in the Fellow Eye

This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the fellow eye (i.e., non-study eye). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity, and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
Reported as:
Count of participants · Participants
Incidence of Ocular Adverse Events in the Fellow Eye
ParticipantsFaricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)
Any Adverse Event (AE)186185179
Serious Adverse Event (SAE)161715
Any AE of Special Interest (AESI)131614
AESI: Drop in Visual Acuity Score ≥30 Letters6910
AESI: Associated with Severe IOI011
AESI: Intervention Required to Prevent Permanent Vision Loss764
AESI: Suspected Transmission of Infectious Agent by Study Drug000
PrimaryIncidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading Scale

This is an analysis of participants with at least one non-ocular (systemic) adverse event (AE). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
Reported as:
Count of participants · Participants
Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading Scale
ParticipantsFaricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)
Any Adverse Event (AE), Any Severity317295297
AE by Severity: Mild919497
AE by Severity: Moderate124124115
AE by Severity: Severe1027785
Serious Adverse Event (SAE)122100112
AE Leading to Withdrawal from Study Treatment274
Any AE of Special Interest (AESI)001
AESI: Drop in Visual Acuity Score ≥30 Letters001
AESI: Elevated ALT or AST with Either Elevated Bilirubin or Clinical Jaundice000

Adverse events

Collected over From the day of the first dose of faricimab until the end of the study (up to 108 weeks). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Faricimab PTI (Prior Faricimab Q8W)23/493 (4.7%)158/491 (32.2%)233/491 (47.5%)
Faricimab PTI (Prior Faricimab PTI)23/506 (4.5%)124/500 (24.8%)213/500 (42.6%)
Faricimab PTI (Prior Aflibercept Q8W)17/475 (3.6%)134/473 (28.3%)219/473 (46.3%)
Most frequent serious events
Showing 10 of 315
Most frequent serious events
EventFaricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)
CataractEye disorders11/4918/50015/473
Cerebrovascular accidentNervous system disorders4/4913/50010/473
COVID-19Infections and infestations10/4919/5005/473
Myocardial infarctionCardiac disorders9/4913/5008/473
Acute kidney injuryRenal and urinary disorders8/4915/5005/473
PneumoniaInfections and infestations5/4918/5003/473
Cardiac failure congestiveCardiac disorders7/4913/5002/473
Diabetic retinal oedemaEye disorders7/4910/5002/473
Localised infectionInfections and infestations7/4910/5002/473
OsteomyelitisInfections and infestations7/4914/5000/473
Most frequent other events
Showing 10 of 14
Most frequent other events
EventFaricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)
CataractEye disorders65/49160/50063/473
COVID-19Infections and infestations63/49149/50046/473
CataractEye disorders56/49141/50051/473
Diabetic retinal oedemaEye disorders22/49127/50024/473
NasopharyngitisInfections and infestations18/49112/50023/473
HypertensionVascular disorders18/49120/50023/473
Posterior capsule opacificationEye disorders13/49120/50013/473
Diabetic retinopathyEye disorders17/4918/50012/473
Posterior capsule opacificationEye disorders16/49117/50014/473
Urinary tract infectionInfections and infestations16/49115/50016/473

Baseline characteristics

A total of 1479 patients consented to enroll in RHONE-X once they completed the parent studies. However, the baseline analysis population includes a total of 1474 participants because 5 participants were excluded from all analyses as an outcome of the GCP non-compliance identified at one of the clinical trial sites.

Age, Continuous
Age, Continuous(Years)Faricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)Total
Mean63.4 ± 9.964.0 ± 9.863.5 ± 9.463.6 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Faricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)Total
Female191184205580
Male302322270894
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Faricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)Total
Hispanic or Latino688779234
Not Hispanic or Latino4154083861209
Unknown or Not Reported10111031
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Faricimab PTI (Prior Faricimab Q8W)Faricimab PTI (Prior Faricimab PTI)Faricimab PTI (Prior Aflibercept Q8W)Total
American Indian or Alaska Native54413
Asian545245151
Native Hawaiian or Other Pacific Islander1012
Black or African American27322584
White3924063891187
More than one race1001
Unknown or Not Reported13121136
08

Study locations

320 sites
  • Barnet Dulaney Perkins Eye Center
    Mesa, Arizona 85206, United States
  • Retinal Research Institute, LLC
    Phoenix, Arizona 85014, United States
  • Arizona Retina and Vitreous Consultants
    Phoenix, Arizona 85016, United States
  • Retina Associates Southwest PC
    Tucson, Arizona 85704, United States
  • California Retina Consultants.
    Bakersfield, California 93309, United States
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • The Retina Partners
    Encino, California 91436, United States
  • Eye Medical Center
    Fresno, California 93720, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835-3424, United States
  • Southern California Permanente Medical Group
    Los Angeles, California 90027, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • East Bay Retina Consultants
    Oakland, California 94609, United States
  • Southern CA Desert Retina Cons
    Palm Desert, California 92211, United States
  • California Eye Specialists Medical group Inc.
    Pasadena, California 91107, United States
  • Retina Consultants, San Diego
    Poway, California 92064, United States
  • Retina Consultants of Southern California
    Redlands, California 92373, United States
  • Retinal Consultants Med Group
    Sacramento, California 95825, United States
  • West Coast Retina Medical Group
    San Francisco, California 94109, United States
  • Orange County Retina Med Group
    Santa Ana, California 92705, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • California Retina Consultants - Santa Maria
    Santa Maria, California 93454, United States
  • Bay Area Retina Associates
    Walnut Creek, California 94598, United States
  • University of Colorado; dept of ophthalmology
    Aurora, Colorado 80045, United States
  • Retina Consultants of Southern
    Colorado Springs, Colorado 80909, United States
  • Colorado Retina Associates, PC
    Lakewood, Colorado 80228, United States
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
  • Rand Eye
    Deerfield Beach, Florida 33064, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Retina Care Specialists
    Palm Beach Gardens, Florida 33410, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Fort Lauderdale Eye Institute
    Plantation, Florida 33324, United States
  • Retina Vitreous Assoc of FL
    St. Petersburg, Florida 33711, United States
  • Southern Vitreoretinal Assoc
    Tallahassee, Florida 32308, United States
  • Retina Associates of Florida, LLC
    Tampa, Florida 33609, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina PC
    Marietta, Georgia 30060-1137, United States
  • Retina Consultants of Hawaii
    ‘Aiea, Hawaii 96701, United States
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
  • Prairie Eye & LASIK Center / Prairie Retina Center
    Springfield, Illinois 62704, United States
  • Midwest Eye Institute
    Indianapolis, Indiana 46290, United States
  • Wolfe Eye Clinic
    West Des Moines, Iowa 50266, United States
  • Retina Associates
    Lenexa, Kansas 66215, United States
  • Vitreo-Retinal Consultants
    Wichita, Kansas 67214, United States
  • Retina Associates of Kentucky
    Lexington, Kentucky 40509, United States
  • Maine Eye Center
    Portland, Maine 04101, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Johns Hopkins Med; Wilmer Eye Inst
    Baltimore, Maryland 21287, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Cumberland Valley Retina PC
    Hagerstown, Maryland 21740, United States
  • Retina Specialists
    Towson, Maryland 21204, United States
  • Tufts Medical Center; Ophthalmology
    Boston, Massachusetts 02111, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Beetham Eye Institute, Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Vitreo-Retinal Associates, PC
    Worcester, Massachusetts 01605, United States
  • Associated Retinal Consultants
    Grand Rapids, Michigan 49546, United States
  • Foundation for Vision Research
    Grand Rapids, Michigan 49546, United States
  • Vitreo-Retinal Associates
    Grand Rapids, Michigan 49546, United States
  • Assoc Retinal Consultants PC
    Royal Oak, Michigan 48073, United States
  • Associated Retinal Consultants, P.C.
    Traverse City, Michigan 49686, United States
  • VitreoRetinal Surgery, PLLC.; DBA Retina Consultants of Minnesota
    Edina, Minnesota 55435, United States
  • Midwest Vision Research Foundation
    Chesterfield, Missouri 63017, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • NJRetina
    Edison, New Jersey 08820, United States
  • Retinal & Ophthalmic Cons PC
    Northfield, New Jersey 08225, United States
  • Retina Associates of NJ
    Teaneck, New Jersey 07666, United States
  • University of New Mexico
    Albuquerque, New Mexico 87131, United States
  • Capital Region Retina
    Albany, New York 12206, United States
  • Long Is. Vitreoretinal Consult
    Great Neck, New York 11021, United States
  • Long Is. Vitreoretinal Consult
    Hauppauge, New York 11788, United States
  • Retina Vit Surgeons/Central NY
    Liverpool, New York 13088, United States
  • New York University
    New York, New York 10017, United States
  • Ophthalmic Cons of Long Island
    Oceanside, New York 11572, United States
  • Retina Associates of Western New York
    Rochester, New York 14620, United States
  • Island Retina
    Shirley, New York 11967, United States
  • The Retina Consultants
    Slingerlands, New York 12159, United States
  • Western Carolina Retinal Associate PA
    Asheville, North Carolina 28803, United States
  • Char Eye Ear &Throat Assoc
    Charlotte, North Carolina 28210, United States
  • Graystone Eye
    Hickory, North Carolina 28602, United States
  • Wake Forest Baptist Health Eye Centre
    Winston-Salem, North Carolina 27157, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Retina Assoc of Cleveland Inc
    Cleveland, Ohio 44122, United States
  • Cleveland Clinic Foundation; Cole Eye Institute
    Cleveland, Ohio 44195-0001, United States
  • The Ohio State University Havener Eye Institute
    Columbus, Ohio 43212, United States
  • Midwest Retina
    Dublin, Ohio 43016, United States
  • Retina Vitreous Center
    Edmond, Oklahoma 73013, United States
  • Retina Northwest
    Portland, Oregon 97221, United States
  • Mid Atlantic Retina - Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Mid-Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
  • Retina Consultants Of Carolina
    Greenville, South Carolina 29605, United States
  • Charleston Neuroscience Inst
    Ladson, South Carolina 29456, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Southeastern Retina Associates Chattanooga
    Chattanooga, Tennessee 37421, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Tennessee Retina PC
    Nashville, Tennessee 37203, United States
  • Retina Res Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Retina Associates
    Austin, Texas 78705-1169, United States
  • Austin Clinical Research LLC
    Austin, Texas 78750, United States

Showing the first 100 of 320 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sheth VS, Schlottmann P, Lai TYY, Abreu F, Chang A, Eter N, Gibson K, Hu AY, Korobelnik JF, Kotak A, Kotecha A, O'Leary OE, Pearce I, Sim DA, Sun JK, Tang Y, Khanani AM. Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial. Ophthalmology. 2026 May;133(5):599-612. doi: 10.1016/j.ophtha.2026.01.001. Epub 2026 Jan 12. PubMed 41534798 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2023, 38 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 38 months is above that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2020
First posted
Jun 16, 2020
StartActual
Aug 5, 2020
Primary completionActual
Oct 11, 2023
CompletionActual
Oct 11, 2023
Results first posted
Oct 30, 2024
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04432831
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Aug 5, 2020
Primary completion
Oct 11, 2023
Completion
Oct 11, 2023
Results posted
Oct 30, 2024
Last update
Feb 9, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion